Attached files
| file | filename |
|---|---|
| EX-4.4 - EX-4.4 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES E - Apellis Pharmaceuticals, Inc. | apls-ex44_92.htm |
| EX-32.2 - EX-32.2 - Apellis Pharmaceuticals, Inc. | apls-ex322_6.htm |
| EX-32.1 - EX-32.1 - Apellis Pharmaceuticals, Inc. | apls-ex321_8.htm |
| EX-31.2 - EX-31.2 - Apellis Pharmaceuticals, Inc. | apls-ex312_11.htm |
| EX-31.1 - EX-31.1 - Apellis Pharmaceuticals, Inc. | apls-ex311_7.htm |
| EX-23.2 - EX-23.2 CONSENT OF EY - Apellis Pharmaceuticals, Inc. | apls-ex232_147.htm |
| EX-21.1 - EX-21.1 - Apellis Pharmaceuticals, Inc. | apls-ex211_9.htm |
| 10-K - 10-K - Apellis Pharmaceuticals, Inc. | apls-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement No. 333-235830 and 333-229091 on Form S-3 and Registration Statement No. 333-229876 and 333-221528 on Form S-8 of our reports dated February 27, 2020, relating to the financial statements of Apellis Pharmaceuticals, Inc. and its subsidiaries and the effectiveness of Apellis Pharmaceuticals, Inc. and its subsidiaries’ internal control over financial reporting appearing in the Annual Report on Form 10-K for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
February 27, 2020